Sargent Investment Group’s Summit Therapeutics SMMT Stock Holding History

Sargent Investment Group’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$175K	–	278
2025 Q4	$175K	Hold	10,000	–	–	0.02%	248
2025 Q3	$207K	Hold	10,000	–	–	0.03%	111
2025 Q2	$285K	Sell	10,000 -500	-5%	-$11.4K	0.04%	197
2025 Q1	$203K	Sell	10,500 -70,000	-87%	-$1.4M	0.03%	221
2024 Q4	$1.46M	Hold	80,500	–	–	0.24%	77
2024 Q3	$1.76M	Buy	80,500 +8,500	+12%	+$119K	0.32%	64
2024 Q2	$562K	Buy	72,000 +62,000	+620%	+$335K	0.11%	112
2024 Q1	$41.4K	Hold	10,000	–	–	0.01%	200
2023 Q4	$26.1K	Hold	10,000	–	–	0.01%	208
2023 Q3	$18.7K	Hold	10,000	–	–	﹤0.01%	202
2023 Q2	$25.1K	Buy	+10,000	New	+$18.3K	0.01%	200

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sargent Investment Group's SMMT Position: Q1 2026 in Review

Sargent Investment Group sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 10,000 shares — an estimated $175K sold.

Sargent Investment Group first reported a position in SMMT in Q2 2023 and held it in 11 quarters. The position peaked at $1.76M in Q3 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Sargent Investment Group reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
Sargent Investment Group sold 10,000 Summit Therapeutics shares in Q1 2026, an estimated $175K.
Sargent Investment Group first reported a position in Summit Therapeutics in Q2 2023 and held it in 11 quarters.
Sargent Investment Group's Summit Therapeutics position peaked at $1.76M in Q3 2024.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Sargent Investment Group's 13F filing for Q1 2026, filed 11 May 2026.